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Amyloid beta (Aβ) is a peptide cleaved from amyloid precursor protein that contributes to
the formation of senile plaques in Alzheimer’s disease (AD). The relationship between Aβ
and astrocyte proliferation in AD remains controversial. Despite pathological findings of
increased astrocytic mitosis in AD brains, in vitro studies show an inhibitory effect of Aβ
on astrocyte proliferation. In this study, we determined the effect of an active fragment
of Aβ (Aβ25−35 ) on the cell cycle progression of primary rat astrocytes. We found
that Aβ25−35 (0.3–1.0 µg/ml) enhanced astrocyte proliferation in vitro in a time- and
concentration-dependent manner. Increased DNA synthesis by Aβ25−35 was observed
during the S phase of the astrocyte cell cycle, as indicated by proliferation kinetics and
bromodeoxyuridine immunocytochemical staining. Aggregation of Aβ25−35 abolished
the upregulatory effect of Aβ on astrocyte proliferation. Further examination indicated
that Aβ25−35 affected astrocyte proliferation during early or mid-G1 phase but had no
effect on DNA synthesis at the peak of S phase. These results provide insight into the
relationship between Aβ25−35 and astrocyte cell cycling in AD.
Keywords: astrocyte, amyloid beta, cell cycle, primary cultures, Alzheimer’s disease

INTRODUCTION
Alzheimer’s disease (AD), the most common form of neurodegenerative disease (Alzheimer’s
Association, 2015), is characterized by two pathological hallmarks: senile plaques composed of
amyloid beta (Aβ) and neurofibrillary tangles made up of hyperphosphorylated tau (Scheltens
et al., 2016). Deposition of Aβ fibrils is an early finding in AD brains (Roth et al., 1966; Pike
et al., 1995a; Rama Rao and Kielian, 2015). Aβ is a peptide that is proteolytically cleaved from
transmembrane amyloid precursor protein (APP) by alpha, beta, or gamma secretases and can
vary in length (LaFerla et al., 2007; Chow et al., 2010). Mutations in either APP or presenilins,
which are the catalytic subunits of the gamma secretase complex, increase the risk for AD, possibly
by elevating the production of abnormal APP cleavage products that are more prone to forming
pathogenic fibrils (Iwatsubo et al., 1994, 1995; Gu and Guo, 2013). Several different Aβ fragments
alter the functions of neurons and glia, including Aβ25−35 (Iversen et al., 1995; Millucci et al., 2010;
Abeti et al., 2011; Dal Pra et al., 2011), Aβ1−42 (Iversen et al., 1995; Dal Pra et al., 2011; Blennow
et al., 2015), Aβ22−35 (Takadera et al., 1993; Iversen et al., 1995), and Aβ12−28 (Iversen et al., 1995;
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newborn (<48 h) Sprague-Dawley rat pups (Harlan Sprague
Dawley, Indianapolis, IN, United States) were harvested and
mechanically dissociated. Astrocytes were isolated by filtration
through nylon mesh with 20 µm pore size to remove
tissue debris (Langan and Slater, 1992; Langan and Chou,
2011). Primary astrocyte cultures were maintained in 10%
fetal bovine serum (Hyclone, Logan, UT, United States)
and 1% penicillin–streptomycin (v/v; Sigma, St. Louis, MO,
United States) in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco/Life Technologies, Inc., Grand Island, NY, United States)
at 37◦ C in a CO2 incubator (5% CO2 /95% humidified air) until
in vitro studies. A previous study shows that the initial astrocyte
cultures generated by this method are of ≥95% purity (Langan
and Chou, 2011; Langan et al., 2017).

Giulian et al., 1996). Each of these species has different
propensities for forming aggregates and senile plaques (Kummer
and Heneka, 2014). Among these Aβ25−35 was also shown to
induce the production of Aβ1−42 in cultured human astrocytes
(Dal Pra et al., 2011). Although Aβ is believed to be critical for the
development of AD, the biology of different peptide species and
their aggregates, as well as the mechanisms by which they drive
pathogenesis remain largely unknown (De Strooper and Karran,
2016).
Interestingly, amyloid deposits and senile plaques are
surrounded by reactive astrocytes (Pike et al., 1995a; Rama Rao
and Kielian, 2015), a phenomenon noted by Alzheimer himself
in his initial pathological analysis and recently confirmed by
others (Alzheimer et al., 1995; Santillo et al., 2011). Although
remaining in a state of quiescence under normal circumstances,
mammalian astrocytes play critical roles in the biochemical and
physiological functions of the central nervous system (Langan,
1993), including shaping synaptic transmission (Murphy-Royal
et al., 2015), regulating cerebral blood flow (Zonta et al.,
2003), and maintaining proper levels of extracellular ions and
neurotransmitters (Simard and Nedergaard, 2004; Olsen et al.,
2015). However, in AD and other pathological conditions,
astrocytes undergo metabolic and phenotypic transformations,
re-entering the cell cycle and actively proliferating, a state known
as reactive astrogliosis (Amaducci et al., 1981; Pekny et al., 2016;
Rodriguez-Arellano et al., 2016). Reactivation of astrocytes is
thought to be a crucial early step in the pathogenesis of AD,
and prevention of astrogliosis has been proposed as a potential
therapeutic strategy (Pekny et al., 2014, 2016; Scholl et al., 2015;
Rodriguez-Arellano et al., 2016). The mechanisms underlying
cell-cycle re-entry in astrocytes and the relationship between
different Aβ species, aggregation states, and reactive astrogliosis
remain a matter of intense debate, and further investigation is
necessary before novel therapeutic strategies can be proposed
(Jordan-Sciutto et al., 2002; Gartner et al., 2003; Yang et al., 2006).
The goal of the present study was to gain a better
understanding of the functional relationship between Aβ and
proliferation of astrocytes. We hypothesized that soluble Aβ, but
not aggregated (agAβ), promotes astrocyte reactivation regardless
of cell-cycle phase. To test this hypothesis, we treated serumdeprived and non-serum-deprived rat astrocytes with Aβ25−35
and measured their rates of proliferation after varying lengths
of time in vitro. We further investigated if aggregation of soluble
Aβ25−35 alters its effects on astrocytes. Our results provide insight
into the functional roles of Aβ25−35 , as well as results of its
aggregation, in reactive astrocytosis.

Astrocyte Subculture and In Vitro
Stimulation
Non-serum-Deprivation Experiments
Primary astrocytes were harvested by trypsinization and passaged
into 6-well plates at a concentration of 1 × 104 cells/cm2 in
10% bovine calf serum (BCS; Hyclone)/DMEM (v/v). After an
initial 2-h incubation at 37◦ C in 5% CO2 /95% humidified air, the
medium was removed, and cell cultures were washed once with
phosphate-buffered saline (PBS, pH 7.4) to remove cell debris and
non-adherent cells; 3 ml of 10% BCS/DMEM was then added to
adherent cells. Astrocytes were allowed to proliferate at 37◦ C in
5% CO2 /95% humidified air for 48 h. At the end of incubation,
the supernatant was replaced with 2 ml fresh 10% BCS/DMEM in
the presence of varying concentrations of agAβ25−35 (in PBS, pH
7.4), freshly prepared non-agAβ25−35 (in PBS, pH 7.4), or control
peptide (CP; Cal-Biochem, La Jolla, CA, United States) (in PBS,
pH 7.4), which was the Aβ fragment of interest with the amino
acids in reverse order (i.e., Aβ35−25 ). This step represented the
start of the experiment (i.e., T 0 ).

Serum-Deprivation Experiments
Astrocytes were passaged into 6-well plates at a concentration of
1 × 104 cells/cm2 in 10% BCS/DMEM. Cells were then allowed
to grow to 30–50% confluence in 10% BCS/DMEM at 37◦ C in 5%
CO2 /95% humidified air. At the end of incubation, the medium
was removed, and cells were rinsed with PBS (pH 7.4). Cells
were then overlaid with 3 ml 0.1% BCS/DMEM and incubated
at 37◦ C in 5% CO2 /95% humidified air for 48 h, such that by
the end of the incubation period, 85–90% of cells entered cellcycle arrest (Langan and Slater, 1991; Chou and Langan, 2003;
Langan and Chou, 2011; Langan et al., 2017). At the end of
the serum-deprivation process, the medium was replaced with
2 ml 10% BCS/DMEM. This serum up-shift allowed astrocytes
to re-enter the cell cycle in a first-order manner and represented
the start of the cell-cycle entry experiment (i.e., T 0 ) (Langan
and Volpe, 1987; Kniss and Burry, 1988; Chou and Langan,
2003; Langan and Chou, 2011; Langan et al., 2017). Varying
concentrations of agAβ25−35 , non-aggregated (freshly prepared)
Aβ25−35 , or CP were added to the cultures concurrently with
the medium, allowing astrocytes to re-enter the cell cycle under
defined experimental conditions.

MATERIALS AND METHODS
Primary Astrocyte Culture
All experimental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at the SUNY at
Buffalo, and all experiments were carried out in accordance
with the approved procedures. Newborn pups were purchased
from Harlan Sprague-Dawley and housed briefly in the Animal
Research Center, SUNY at Buffalo. The cerebral cortices of
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Manville, NJ, United States), and the total cellular protein in the
samples was determined by Bradford assay (BioRad, Hercules,
CA, United states) using a microplate reader (model 3550UV; BioRad, Hercules, CA, United states) at a wavelength of
595 nm.

Aβ25−35 and Its Aggregation
The Aβ25−35 peptide is a truncated product of Aβ that was
shown to be physiologically active, and was widely published
in articles using rat models of AD (Soto et al., 1998; Arif
et al., 2009; Fedotova et al., 2016; Nell et al., 2016; Soultanov
et al., 2016). Others have shown that the effects of Aβ25−35
on different cellular functions in both astrocytes and neurons
are similar to those of Aβ1−42 (Chiarini et al., 2010; Kaminsky
et al., 2010); additionally, although its physiologic role remains
unclear, histopathological studies have shown that Aβ25−35 is
present in senile plaques of Alzheimer’s brains (Kubo et al.,
2003). For these reasons, Aβ25−35 is the focus of the present
studies using rat astrocytes. Quantitative analysis of Aβ25−35
aggregation by sedimentation assay was performed according
to an established procedure (Pike et al., 1994, 1995b). In
brief, the lysine residues in the non-agAβ25−35 fragment react
with the fluorescent marker fluorescamine (FLCN; Molecular
Probes, Inc., Eugene, OR, United States). Aggregation of the
Aβ25−35 fragments is measured by a decrease in the number
of lysine residues available to bind to FLCN, resulting in a
reduction in fluorescence intensity proportional to the extent
of aggregation. Different concentrations of Aβ25−35 and CP
were solubilized in 1 ml PBS (pH 7.4) at room temperature
(RT) for 2 or 48 h. Aliquots of the FLCN solution in
acetonitrile were added to each set of samples to achieve a
1:1 mol/ml ratio of peptide to FLCN. Following the addition
of FLCN, half of the samples were measured for FLCN
fluorescence without centrifugation, and half were centrifuged
at 100,000 × g for 1 h, and the supernatant was used to
measure FLCN fluorescence (Pike et al., 1995b). Fluorescence
was measured at 478 nm by exciting the peptide at 383 nm
with a fluorescence (LS-5) spectrophotometer (Perkin-Elmer,
Norwalk, CT, United States) (De Bernardo et al., 1974; Alavi et al.,
2013).

BrdU Incorporation Assay
The number of cells undergoing active DNA synthesis
was quantified by immunocytochemical staining for
bromodeoxyuridine (BrdU) (Sigma) (Yong et al., 1988;
Langan and Slater, 1991). Primary astrocyte cultures were
passaged onto 4.9 mm2 glass cover slips coated with polylysine (Sigma) in 12-well plates, grown to 30–50% confluency,
and rendered into cell cycle arrest by serum deprivation as
described above. Serum-deprived astrocytes were then allowed
to re-enter the cell cycle under experimental conditions. To
identify cells undergoing active DNA synthesis, BrdU was
added to cell cultures at a final concentration of 15 µM for
a period of 2.5 h prior to the termination of experiments.
At the end of incubation, the cover slips were removed
and rinsed with PBS (pH 7.4) followed by fixation with 4%
paraformaldehyde (PFA; Sigma) in PBS (pH 7.4) for 10 min
at RT. After fixation, the 4% PFA was aspirated, and cells
were washed twice with PBS (pH 7.4). Fixed cells were then
treated with 2 M HCl (10 min, RT) to permeabilize the
nuclear membrane. The HCl was removed, and cells were
again washed twice with PBS (pH 7.4) followed by incubation
with 0.1 M NaB4 O7 to neutralize the HCl (10 min, RT).
After acid neutralization, the NaB4 O7 was removed, and cells
were washed three times with PBS (pH 7.4). Next, cells were
blocked with 5% bovine serum albumin in PBS (20 min,
RT). Monoclonal antibody for BrdU (Sigma) was added at
a dilution of 1:200 for 1 h at RT followed by the addition of
goat anti-rat rhodamine-labeled secondary antibody (Sigma)
at a dilution of 1:200 for 30 min. The percent of BrdU+
nuclei was calculated based on the cell count in each of
the randomly selected high powered fields using a phasefluorescent microscope (Langan and Slater, 1991; Li et al.,
1996).

Cell Proliferation Assays
3 H-Thymidine

Incorporation Assay

The incorporation of tritiated [methyl-3 H]-thymidine into
primary astrocytes was used to quantify cell proliferation
according to established procedures (Langan and Volpe, 1987;
Langan and Slater, 1992; Chou and Langan, 2003; Langan
and Chou, 2011; Langan et al., 2017). Radio-labeled [methyl3 H]-thymidine (25 Ci/mmol; Amersham, Arlington Heights,
IL, United States) was added to each well 1 h prior to the
termination of the experiment at a final activity of 1.0 µCi/ml
(37◦ C, 5% CO2 /95% humidified air). At the end of the
incubation, cultures were washed with 2 ml Tris–EDTA buffer
(pH 7.4) twice to remove any excess 3 H-thymidine. DNA and
total cellular protein were extracted using the trichloroacetic
acid precipitation method (Langan and Volpe, 1987; Langan
and Slater, 1992). Cell proliferation was measured as the
incorporation of radioactivity per microgram of protein present
in the acid-precipitated portion (cpm/µg protein). Tritium
was quantified in the samples with a beta counter (LKB
Wallac, Gaithersburg, MD, United States) for 10 min using an
Ecoscint-A liquid scintillation cocktail (National Diagnostics,
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Cell Viability
In parallel to the cell proliferation assays, an identical set of cells
was subcultured and treated as described above for each set of
experiments. At the end of each time point, cells were harvested
by trypsinization, centrifuged, and resuspended in PBS. A 0.4%
trypan blue solution (Sigma) was added to the cell suspension
in a 1:1 v/v ratio. A manual cell count was performed using a
hemocytometer.

Statistical Analysis
All experiments were repeated at least three times, and all
conditions were performed in triplicate. Data were expressed
as mean ± standard error of the mean (SEM) and analyzed
using Student’s t-tests for unpaired comparisons and one-way
ANOVA for multiple group comparisons. Statistical significance
was defined as p < 0.05.
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RESULTS
Aβ25−35 Upregulates Proliferation of
Non-serum-Deprived Astrocytes in a
Time- and Concentration-Dependent
Manner
We first examined the effect of Aβ25−35 on astrocyte
proliferation by measuring DNA synthesis of non-serumdeprived primary astrocytes treated with freshly prepared and
graded concentrations of Aβ25−35 (0.01–3.0 µg/ml). Astrocytes
proliferated in an exponential-like manner over a 48-h period,
with a lag phase in the initial 24 h, a log phase in the next 12 h
(24–36 h), and a slowed rate of proliferation in the last 12 h tested
(36–48 h). We found that Aβ25−35 increased the rate of DNA
synthesis in primary astrocytes in a time- and concentrationdependent manner (Figure 1A). At a concentration of 0.3 µg/ml,
Aβ25−35 only caused a significant increase in DNA synthesis after
48 h of incubation compared with control. The greatest effect
on astrocyte proliferation was obtained using a concentration of
1.0 µg/ml Aβ25−35 , which caused significant increases in DNA
synthesis after 24, 36, and 48 h of incubation. A further increase
in the concentration of Aβ25−35 to 3.0 µg/ml did not upregulate
the rate of astrocyte proliferation at any time point, which
therefore followed a classical concentration-effect response
(Figure 1A). Based on these findings, we utilized Aβ25−35 at a
concentration of 1.0 µg/ml in subsequent experiments.
We next examined the specificity of the response to Aβ25−35 by
treating primary astrocytes with either Aβ25−35 or CP consisting
of the reversed amino acid sequence (i.e., Aβ35−25 ) at varying
concentrations for 36 or 48 h. CP did not upregulate DNA
synthesis in primary astrocyte cultures compared with control
at either time point or either concentration tested (Figure 1B),
supporting the notion that the increased proliferation of
astrocytes in response to Aβ25−35 depends on its amino acid
sequence.

FIGURE 1 | The effect and specificity of Aβ25−35 on proliferation of
non-serum-deprived primary astrocytes. (A) Subcultured astrocytes were
incubated with graded concentrations of freshly prepared and solubilized
Aβ25−35 or control. 3 H-thymidine was added to cultures 1 h prior to
termination. Cultures were terminated every 12 h and processed for
3 H-thymidine uptake to measure rate of DNA synthesis. (B) Subcultured
astrocytes were incubated with freshly prepared Aβ25−35 or CP at various
concentrations for 36 or 48 h. Rate of DNA synthesis was measured using
3 H-thymidine incorporation assay. ∗ p < 0.05; ∗∗ p < 0.02; ∗∗∗ p < 0.001
(results were average values of three representative experiments).

Aβ25−35 Upregulates DNA Synthesis
During S Phase in Serum-Deprived
Primary Astrocytes
We next addressed whether Aβ25−35 affects cell-cycle kinetics of
astrocytes in vitro. Astrocytes were first subcultured in serumdeprived medium that rendered cell-cycle arrest. Astrocytes
were then exposed to serum up-shift (Langan and Chou,
2011; Langan et al., 2017), resulting in re-entry into the cell
cycle with highly replicable kinetics (Figure 2). Consistent
with previous studies (Langan and Slater, 1992; Langan, 1993),
following serum up-shift, astrocytes remained in G1 phase for
12 h and then entered the S phase for the next 12 h, as
shown by a first-order increase in DNA synthesis (Figure 2).
When astrocytes re-entered the cell cycle in the presence of
Aβ25−35 (1 µg/ml), the rate of proliferation was significantly
upregulated compared with CP-treated astrocytes (Figure 2).
Aβ25−35 did not impact the length of G1 or increase the
rate of proliferation of astrocytes during this time, suggesting
that the effect of Aβ25−35 on astrocytes is restricted to S

Frontiers in Cellular Neuroscience | www.frontiersin.org

phase. Additionally, altered proliferation in serum-deprived
astrocytes was specifically mediated by Aβ25−35 , as CP did
not significantly impact DNA synthesis compared with control
(Figure 2).
We confirmed these findings using immunocytochemical
staining for BrdU (Figure 3 and Table 1) and quantifying
the percent of BrdU+ cells at T 0 and T 24 in the presence
or absence of Aβ25−35 (1 µg/ml). Following 48 h of serum
deprivation (i.e., T 0 ), more than 81% of cells were in a state
of quiescence (Figure 3 and Table 1). At T 24 , the peak of S
phase, about 65% of the cells were BrdU+, indicating that they
had re-entered the cell cycle and undergone active proliferation
(Figure 3 and Table 1). In the presence of Aβ25−35 , significantly
more astrocytes re-entered the cell cycle, as indicated by BrdU+
staining (Figure 3 and Table 1). This increase in the percentage
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TABLE 1 | Percent of BrdU+ astrocytes in response to various treatments for
24 h.
Treatment
Control

Time point (hour)

Mean ± SEM (%)

0

18.38 ± 0.02

24

65.42 ± 0.02

Aβ25−35

24

87.35 ± 0.02∗

CP

24

62.44 ± 0.02

∗p

< 0.005.

Aggregation of Aβ25−35 Impairs Its Effect
on Proliferation Rate in
Non-serum-Deprived Astrocytes
In order to generate agAβ25−35 , we allowed graded
concentrations of Aβ25−35 to aggregate for 2 or 48 h;
aggregation was confirmed by measuring FLCN incorporation.
Aggregation was compared in two different manners: (1)
time-dependent effect in the non-centrifugation portion,
i.e., 2 vs. 48 h, as represented by the statistical symbol
“∗ ” and (2) concentration-dependent effect in each time
point, i.e., suspension vs. supernatant, as represented
by the statistical symbol “† ”. We observed a significant
decrease in fluorescence after 48 h at all concentrations
of Aβ25−35 (0.5–10.0 µg/ml) when compared with 2 h
incubation (Table 2), both in the non-centrifuged solution
and in the supernatant of the centrifuged solution. These

FIGURE 2 | The effect of Aβ25−35 on proliferation of serum-deprived primary
astrocytes. Newborn astrocytes were rendered into G0 phase by serum
deprivation and then allowed to re-enter the cell cycle via serum up-shift in the
presence of freshly prepared Aβ25−35 (1.0 µg/ml) or CP (1.0 µg/ml).
3 H-thymidine incorporation assay was performed to measure rate of DNA
synthesis. ∗ p < 0.05; ∗∗ p < 0.02; ∗∗∗ p < 0.001 (results were average values
of three representative experiments).

of BrdU+ cells was specific to Aβ25−35 treatment, as there was
no significant change in the percentage of BrdU+ cells after
24 h of incubation with CP (Figure 3 and Table 1) compared to
control.

FIGURE 3 | The effect of Aβ25−35 on BrdU incorporation in serum-deprived primary astrocytes. Newborn astrocytes were serum deprived for 48 h, resulting in cell
cycle arrest, as demonstrated by low BrdU+ cell count (A; 18.38 ± 0.02%, n = 9, total cell count = 102). Following serum deprivation, cells were stimulated to
re-enter the cell cycle in the presence of either freshly prepared Aβ25−35 (1.0 µg/ml) or CP (1.0 µg/ml). BrdU was added to the cultures 2.5 h prior to termination.
After 24 h of incubation, samples were processed for immunocytochemical staining of BrdU. There was no significant difference in the number of BrdU+ cells
between the control (B; 65.42 ± 0.02%, n = 11, total cell count = 104) and CP-treated astrocytes (D; 62.44 ± 0.02%, n = 11, total cell count = 100). Significantly
more Aβ25−35 -treated astrocytes were BrdU+ (C; 87.35 ± 0.02%; n = 11, total cell count = 102, p < 0.001) compared to controls. Images were taken with
fluorescence microscopy.
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TABLE 2 | Effect of time and fraction on Aβ25−35 aggregation in solution‡ .
[Aβ25−35 ] (µg/ml)

0.5
1.0

Centrifugation

2 h, mean fluorescence
intensity ± SEM

48 h, mean fluorescence
intensity ± SEM

−

3.20 ± 1.21

1.20 ± 0.18∗

+

2.00 ± 0.77

0.9 ± 0.08∗ †

−

11.40 ± 0.63

4.00 ± 0.31∗∗∗∗
3.60 ± 0.85∗∗∗ †††

+

9.60 ± 2.44

3.0

−

34.20 ± 1.76

+

21.5 ± 4.00

9.00 ± 0.76∗∗ ††

10.0

−

187.5 ± 5.46

99.20 ± 4.41∗∗∗∗

+

136.50 ± 4.37

‡ Fluorescence

22.70 ± 0.76∗∗

47.20 ± 2.73∗∗∗∗ ††††

intensity is measured in arbitrary units.; ∗ † p < 0.025; ∗∗ †† p < 0.001; ∗∗∗ ††† p < 0.005; ∗∗∗∗ †††† p < 0.0005.

Exposure to Aβ25−35 During G1 Phase Is
Required to Stimulate Proliferation of
Serum-Deprived Astrocytes
Finally, we examined whether the effect of Aβ25−35 on astrocyte
proliferation is phase-specific. Aβ25−35 or CP (1.0 µg/ml) was
added to serum-deprived astrocyte cultures at the time of
serum up-shift or various times after serum up-shift (T 6 , T 12 ,
and T 16 ). All cultures were terminated at the peak of the S
phase (T 24 ), and the rates of proliferation were determined
using 3 H-thymidine incorporation. Consistent with our earlier
results, we found that adding Aβ25−35 at T 0 significantly
increased the rate of DNA synthesis at the peak of S phase
(T 24 ) compared with control or CP (p < 0.001; Figure 5A).
When Aβ25−35 was added in the middle of G1 phase at T 6 ,
we observed a similar increase in the rate of DNA synthesis
compared with CP or control (p < 0.02). However, when
addition was delayed until the G1 /S phase transition point
(T 12 ) or until the initiation of S phase, the rates of astrocyte
proliferation were not significantly different among the Aβ25−35 ,
CP, and control groups (Figure 5A), suggesting that the effect
of Aβ25−35 on astrocyte proliferation is phase-specific, and
initiated during the G1 phase and before G1 /S phase transition
point.
We further defined the critical period of Aβ25−35 exposure
by using a “delayed addition and early removal” paradigm.
In these experiments, we added Aβ25−35 to the cultures at
different points of the cell cycle and then changed the medium
to remove Aβ25−35 after varying exposure durations (3, 6, or
7 h); all cultures were terminated at the peak of the S phase
(T 24 ), and the rate of proliferation was determined using 3 Hthymidine incorporation. We found that Aβ25−35 significantly
increased the rate of astrocyte proliferation as compared to
control only if it was added to the culture during early to
mid-G1 phase (T 0 , T 3 , or T 6 ; Figure 5B). When Aβ25−35 was
added to the cultures in late G1 phase (T 9 ), there was no
significant difference in the rate of DNA synthesis compared
with control (Figure 5B), regardless of whether the exposure
duration was 3 (T 9 –T 12 ) or 7 h (T 9 –T 16 ). CP did not alter
the rate of DNA synthesis during any of these exposure
periods (data not shown). These results suggest that Aβ25−35
affects the proliferation of astrocytes during early-to-mid-G1
phase.

FIGURE 4 | The effect of Aβ25−35 aggregation on the proliferation of
non-serum-deprived primary astrocytes. Freshly prepared Aβ25−35 was
allowed to aggregate in PBS (pH 7.4) for 48 h; aggregation was confirmed by
FLCN incorporation assay (Table 2). Non-serum-deprived astrocytes were
treated with varying concentrations of agAβ25−35 (0.01–3.0 µg/ml), and
3 H-thymidine incorporation assay was performed to measure rate of DNA
synthesis. ∗ p < 0.05; ∗∗ p < 0.02; ∗∗∗ p < 0.001 (results were average values
of three representative experiments).

data suggest that incubating the peptide at RT for 48 h
results in the formation of aggregates, as evidenced by the
decreased FLCN absorbance in the supernatants of samples
that were solubilized for 48 h as compared to those that
were solubilized for 2 h prior to centrifugation. Based
on our findings, non-centrifuged solutions were used for
downstream experiments in order to ensure that astrocytes
were exposed to aggregates of varying sizes. To address
the question of whether oligomerization of Aβ25−35 affects
astrocyte proliferation, we treated non-serum-deprived
primary astrocyte cultures for 12, 24, 36, or 48 h with
graded concentrations of agAβ25−35 or non-agAβ25−35 . In
contrast to our earlier findings using Aβ25−35 (Figure 1A),
agAβ25−35 only significantly increased the rate of proliferation
of non-serum-deprived astrocytes compared with control
after 24 h of stimulation at a concentration of 3.0 µg/ml
(Figure 4).
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FIGURE 5 | Temporal effects of Aβ25−35 on the proliferation of serum-deprived primary astrocytes. Newborn astrocytes were first serum-deprived and then
re-entered into the cell cycle by serum up-shift. (A) Left, experimental approach; Right, Aβ25−35 (1.0 µg/ml) or CP (1.0 µg/ml) was added to the cultures at varying
times after serum up-shift (0, 6, 12, or 16 h). (B) Left, experimental approach; Right, Aβ25−35 (1.0 µg/ml) was added to the cultures at different time points and then
removed via medium changes after 3, 6, or 7 h of incubation. All cultures were terminated at T 24 , and 3 H-thymidine incorporation assay was performed to measure
rate of DNA synthesis. ∗ p < 0.05; ∗∗ p < 0.02; ∗∗∗ p < 0.001 (results were average values of three representative experiments).

Aβ25−35 upregulates proliferation in both serum-deprived and
non-serum-deprived astrocytes in time- and concentrationdependent manners as measured by 3 H-thymidine incorporation
assay and BrdU staining (Figures 1, 2); importantly, Aβ25−35 did
not induce cellular death in our experiments, as demonstrated
by minimal cell death in trypan blue exclusion assay (<2%). We
found that CP (Aβ35−25 ) did not impact astrocyte proliferation,
confirming the bio-specific effect of Aβ25−35 on the rate of
DNA synthesis in primary astrocytes depends on its amino acid
sequence (Figures 1, 2). Although increasing the concentration
of Aβ25−35 upregulated the rate of proliferation over a certain
range (i.e., 0.01–1.0 µg/ml), showing a clear concentration-effect
of Aβ25−35 on DNA synthesis in astroctyes, further increase
of the Aβ25−35 concentration to 3.0 µg/ml failed to enhance
DNA synthesis (Figure 1). While our data demonstrate a
narrow concentration-effect window, this phenomenon has
been reported in other biological systems, including that seen in
astrocytes. For example, it was shown that just a 1% change in
the concentration of isoflurane had a dramatic effect on astrocyte
calcium signaling in ferret visual cortex (Schummers et al., 2008).
Similarly, it has been shown that mitochondrial function is
extremely sensitive to a narrow range of Ca2+ ion concentrations
(Schild et al., 2005), as is cellular survival in response to free zinc
ions (Bozym et al., 2010). While the mechanisms underlying the
concentration effects of each of these phenomena are currently
unknown, one potential explanation of our data is that Aβ25−35
follows a classical concentration-effect response via specific

DISCUSSION
A definitive diagnosis of AD is based on histopathological
evidence at autopsy or brain biopsy, including the presence of
Aβ deposits, neuritic changes with formation of paired helical
filaments and hyperphosphorylated tau, and reactive astrogliosis
(Serrano-Pozo et al., 2011). Astrocytosis is widespread in the early
phases of AD but declines as the disease progresses, indicating
that gliosis may be an early pathogenic event (Pike et al.,
1995a; Santillo et al., 2011; Rodriguez-Vieitez et al., 2015, 2016;
Scholl et al., 2015). In vitro studies consistently demonstrate
that Aβ is neurotoxic and consequently induces neuritic
changes (Sendrowski et al., 2015; Sadleir et al., 2016). Although
pathological studies show that Aβ-containing senile plaques are
often surrounded by reactive astrocytes, the relationship between
different Aβ species and functional changes in astrocytes is less
clear. Here, we hypothesize that Aβ25−35 increases astrocyte
proliferation, but that aggregation of Aβ25−35 inhibits this effect.
Interestingly, although aberrant expression of mitotic
regulators, such as cyclin c and binding partner Cdk8 have been
observed in the astrocytes of AD brains (Ueberham et al., 2003),
in vitro studies demonstrate highly variable and contrasting
effects of Aβ on astrocytes (Agostinho et al., 2010), including
induction of apoptosis (Brera et al., 2000; Hou et al., 2011; Saha
and Biswas, 2015) and oxidative stress (Brera et al., 2000), as well
as changes in morphology (Salinero et al., 1997) and proliferation
(Hernandez-Guillamon et al., 2009). Our results show that
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receptors; however, further research is required in order to
elucidate the molecular basis of this response (Salinero et al.,
1997; Brera et al., 2000; Hou et al., 2011; Saha and Biswas,
2015). Our data showing narrow effective concentration range
on astrocyte proliferation do suggest a plausible explanation for
astrocyte toxicity in advanced AD. In fact, others have shown that
Aβ25−35 is cytotoxic to astrocytes, those studies were carried out
using concentrations 1000-fold higher than our current study;
therefore, our results do not exclude the findings that high doses
of Aβ25−35 can be cytotoxic to astrocytes in vitro.
Our findings also demonstrate that the effect of Aβ25−35
is cell cycle phase-specific. First, Aβ25−35 increases the rate
of DNA synthesis in serum-deprived astrocytes during the S
phase but not during G1 phase (Figure 2). Second, the timing
of exposure to Aβ25−35 was critical. To upregulate astrocyte
proliferation, Aβ25−35 needed to be added to astrocytes during
early-to-mid-G1 phase. If Aβ25−35 was added any later than 6 h
into G1 , the rate of proliferation was not impacted (Figure 5).
These findings offer novel insights into the effect of Aβ25−35
on astrocyte proliferation, and the mechanisms underlying
the phase specificity are currently under investigation in our
laboratory.
We showed that aggregation of Aβ25−35 impaired its
upregulatory effect on astrocyte proliferation, as agAβ25−35
increased DNA synthesis relative to control only at a
concentration of 3.0 µg/ml and only at T 24 (i.e., 12 h into
the S phase, Figure 4). Senile plaques, a hallmark feature of
AD pathology, are made up of fibrillar or β-sheet aggregates
of amyloid peptide; amyloid deposition has been shown to
occur progressively over the course of the disease and has been
proposed as a biomarker for disease staging (Jack et al., 2013).
However, our results clearly show that aggregation of amyloid
peptide limits its ability to stimulate astrocytes. As astrocyte
activation precedes plaque formation in AD patients (RodriguezVieitez et al., 2015), it is conceivable that initial Aβ deposition
increases astrocyte proliferation and leads to reactive astrocytosis
during the early stages of amyloid deposition, but that as senile

plaques by amyloid aggregation are formed, the rate of astrocyte
reactivation slows down.
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